Marcus Anderson

Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Terra Tech Corp (OTCMKTS:TRTC) Strengthens Operations

Terra Tech Corp (OTCMKTS:TRTC)

Terra Tech Corp (OTCMKTS:TRTC) has signed a non-binding letter of intent paving way for it to complete the acquisition of a 50% stake in NuLeaf Sparks Cultivation LLC and NuLeaf Reno Production LLC. The acquisition should strengthen the company’s cannabis cultivation and production portfolio allowing it to introduce new wholesale cannabis brands in the market.

Terra Tech Corp (OTCMKTS:TRTC)
One month TRTC Stock Price Chart

Investors Reaction

Investors reacted to the acquisition push, sending the stock up 10.19%. TRTC stock is currently trading in a tight $0.22 to $0.26 trading range, waiting to see if the bullish momentum is strong enough to push it to 52-week highs of $0.56 a share. Terra Tech faces resistance at the $0.26 mark.

Terra Tech Corp (OTCMKTS:TRTC) is a cannabis focused Agriculture Company that operates through Hydroponic produce and Cannabis products. The company designs, develops, and markets hydroponic equipment in addition to hydroponic produce and floral products.

NuLeaf Acquisition

The acquisition of NuLeaf Sparks should strengthen the company’s cultivation business given that the company owns a medical cannabis cultivation license. The firm is also in the process of constructing a 30,000 square foot cannabis cultivation facility in Nevada.

NuLeaf Reno holdings, on the other hand, should strengthen the company’s production business as it holds a cannabis production license and is in the process of constructing 15000 square foot facility. Terra Tech Corp (OTCMKTS:TRTC) CEO, Derek Peterson believes the merger will help the company become a dominant force in Nevada legal cannabis business.

“This partnership will allow us to rapidly increase our time to market without needing to invest vast amounts of time or CapEx into establishing cultivation and production capabilities from scratch,” said Mr. Peterson.

The executive remains confident of the transaction closing in the third quarter thus allowing Terra Tech Corp (OTCMKTS:TRTC) to start generating revenues from joint operations before the end of the year. The new cultivation and production facilities will supply three of the company’s dispensaries in addition to third-party dispensaries in the state.

Separately, Terra Tech Corp (OTCMKTS:TRTC) subsidiary Edible Green has expanded its product line with the introduction of a new line of fresh cut herbs dubbed ‘Snip Its’. The new line of product is to go on sale in major retail outlets that support health and wellness.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TRTC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Tandem Diabetes Care Inc (NASDAQ:TNDM)

Stock Soaring for Tandem Diabetes Care Inc (NASDAQ:TNDM)

Tandem Diabetes Care Inc (NASDAQ:TNDM)

Tandem Diabetes Care Inc (NASDAQ:TNDM) stock is up over 50% in early trading on volume, that if continued, would be over 100 times their 30-day, daily average. The market is responding to news that the U.S. Food and Drug Administration (FDA) approved the commercial launch of the t:slim X2™ Insulin Pump with Dexcom G5® Mobile continuous glucose monitoring (CGM) integration. This technology is the first sensor-augmented insulin pump approved to let users make treatment decisions without the need for pricking one’s finger.

About Tandem Diabetes Care Inc.

San Diego, CA-based Tandem Diabetes Care Inc (NASDAQ:TNDM) is a medical device company. The company designs, develops, and commercializes medical deices for people with insulin-dependent diabetes. The company’s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, along with a disposable insulin cartridge, and an infusion set. The company also offers its Tandem Device Updater. This web-based system lets users update their pump’s software and adjust the t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters.

TNDM Stock Performance

Tandem Diabetes Care Inc (NASDAQ:TNDM)
One month stock price chart for TNDM

Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) closed Friday at $0.70, then gapped up to open at $0.92 before hitting its inter-day high (a/o 10:45 AMEST) of $1.22. TNDM stock has performed poorly tear-to-date and lost over 67%. For the year they have dropped almost 90%. The company has not been kind to shareholders on the earnings side either. For 2016, the company had an EPS loss of (-$2.73) and has not posted a profit in the past four years. However, sales have been steadily improving. In 2012 the company posted sales of $2.5 million. That annual figure has improved every year and in 2016 the company reported $84.2 million in sales. The analyst’s consensus price target for TNDM stock is $2.88.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TNDM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Origin Agritech Ltd. (NASDAQ:SEED)

Origin Agritech Ltd. (NASDAQ:SEED) Receives Payment For Seed Business

Origin Agritech Ltd. (NASDAQ:SEED)

Shares of Origin Agritech Ltd. (NASDAQ:SEED) rallied 21.62% after the company announced it had received RMB 152 million as the first batch payment of RMB421 with regard to the sale of its corn seed production and distribution business to Beijing Shihui.  The selloff is part of a restructuring push that seeks to align the company’s operations to leading agricultural biotechnology and corn seed breeding programs.

Origin Agritech Ltd. (NASDAQ:SEED)
One month stock chart for SEED

Stock Performance

Shares of Origin Agritech Ltd. (NASDAQ:SEED) are currently trading in an upward trend after bouncing back from this year’s low of $1.40 a share. The stock is trading in a tight $1.51 to $1.96 trading range with immediate resistance at the $1.90 mark, above which it could rise to $2.20 mark.

Origin Agritech Ltd. (NASDAQ:SEED) is an agricultural biotechnology company specializing in the development, production, and distribution of hybrid seeds. The company also specializes in crop seed breeding, genetic improvement, and related technical services.

In April, Origin Agritech Ltd. (NASDAQ:SEED) sold its Corn, seed production and distribution business as it sought to reposition its commercial seed business for stronger future growth. Under the terms of an agreement, Beijing Shihui is to make an additional payment of RMB 69 Million, before November 15, 2017.

The buyer is also to make a final payment of RMB 200 million including an initial RMB 10 million down payment, no later than December 15, 2017. Origin Agritech Ltd. (NASDAQ:SEED) also retained its corn breeding and biotech research programs as well as all intellectual properties as part of the sell-off agreement.

Origin Agritech Big Play

The company’s chief executive officer, Bill Niebur, expects proceeds from the sale to spearhead the company’s journey to becoming a leading international corn seed technology company.

“The proceeds significantly accelerate and expand our capabilities to develop and deliver corn biotechnology traits and corn product licensing business within China and around the globe. All current indicators point to a near-term commercial launch for the projected USD 5-6 billion GM-trained corn seed market in China,” said Mr. Niebur.

Origin Agritech Ltd. (NASDAQ:SEED) already boasts of a leading corn, germplasm collection and biotech trait platform that it plans to use to address strong customer demand for superior products. The company is also eyeing strategic partnerships with leading agricultural multinationals and Chinese seed companies as it looks to pursue growth opportunities in China’s seed market.

Separately. Mr. Niebur recently purchased 73, 530 of the company’s treasury shares valued at $100,000. The private placement purchase occurred at a purchase price of $1.36 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SEED and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

CareDx Inc (NASDAQ:CDNA)

CareDx Inc (NASDAQ:CDNA) Explodes On Medicare Coverage Approval

CareDx Inc (NASDAQ:CDNA)

Shares of CareDx Inc (NASDAQ:CDNA) rallied 33.022% as investors reacted to the approval of the company’s transplant surveillance solution, AlloSure, for Medicare coverage. The Center for Medicare and Medicaid Services have already released the final version of the coverage policy that paves way for the solution to be made available in hospitals starting October.

CareDx Inc (NASDAQ:CDNA)
One month stock price chart for CDNA

Stock Performance

Medicare approval of AlloSure continues to fuel renewed investor interest on CareDx Inc (NASDAQ:CDNA), which has been under immense selling pressure for the better part of the year. However, Wednesday’s rally reaffirmed a bullish rally that began early in the month. The stock faces immediate resistance at the $3.07 mark above which it could rise to the $4 mark.

CareDx Inc (NASDAQ:CDNA) is a molecular diagnostic company focused on the development of solutions for monitoring transplant patients. Its lead product is the AlloMap heart transplant molecular test, designed to help clinicians monitor and identify heart transplant recipients. AlloSure, on the other hand, is a transplant surveillance solution that applies next generation sequencing to detect genetic differences between donors and recipients.

AlloSure Medicare Coverage

CareDx Inc. (NASDAQ:CDNA) has already hit the ground running in its bid to make AlloSure available on all transplant centers across the U.S, following the Medicare milestone. The company expects increased interest on AlloSure given that Medicare usually covers about 80% of kidney transplant patients.

“We are hearing great interest from transplant nephrologists who want to begin using AlloSure as soon as CMS approval is finalized. We see the coverage decision by the MolDX team as a great signal for the support of kidney transplant patients and an acknowledgment of the unmet medical need,” said Peter Maag, Chief Executive Officer.

Medicare coverage should go a long way in strengthening CareDx Inc (NASDAQ:CDNA) high-value diagnostic solutions portfolio that already boasts of AlloMap in use in heart transplant centers. AlloMap is slowly becoming a standard care for monitoring heart transplant patients for the probability of rejection.

Q2 Earning Report

Medicare approval marks yet another milestone in CareDx Inc. (NASDAQ:CDNA) growth trajectory that became clear with the posting of stellar second quarter earnings. During the quarter, the company generated revenues of $12 million up from $10.7 million reported in Q2 2016. Net loss in the quarter more than halved to $4 million compared to $10.5 million reported last year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CDNA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

MassRoots Inc (OTCMKTS:MSRT)

MassRoots Inc (OTCMKTS:MSRT) Acquisition Lifts Shares

MassRoots Inc (OTCMKTS:MSRT)

MassRoots Inc (OTCMKTS:MSRT) stock is up over 10% in mid-morning trading on heavy volume. The stock’s move comes on the heels of the company announcement of a $12 million acquisition for Cannaregs, Inc. – a technology platform that monitors and alerts users to regulatory and legislative changes regarding the legal cannabis industry. The announcement lifted MSRT stock above its flirtation with its 52-week low of $0.38 and was trading around $0.47 at 11AM EST.

MassRoots Inc (OTCMKTS:MSRT)
One month stock price chart for MSRT

Amanda Ostrowitz founded Cannaregs, Inc. in 2014. The privately held company is cash-flow positive and debt-free with more than $450,000 in annually recurring, contractually-obligated revenue. The service is seen by many in the legal cannabis industry as a “must have” to minimize their businesses regulatory risk. To demonstrate the potential regulatory complexity all one has to do is look at California which has 539 local jurisdictions with different regulations, tax rates, and zoning laws related to the legal cannabis industry.

MassRoots is a social media platform used by recreational consumers of cannabis. Users access the platform through an App and share experiences and ratings of different strains, and forms, of cannabis and cannabis oriented products such as food items or sleep aids. The site was lucky enough to experience viral growth among its APP users. MassRoots popularity even took on tech giant Apple. In late 2014, Apple’s App store was declining to continue to offer the free MassRoots App and went so far as to publish a rule that all cannabis social networks were banned from their App platform. What followed may have made history. An email campaign was started by MassRoots’ users and fans. A letter was authored and signed by dozens of business leaders in the cannabis industry. In less than 60 days, Apple reversed their policy and allowed the MassRoots App into their online store.

I  have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MSRT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

WMIH Corp. (NASDAQ:WMIH)

WMIH Corp. (NASDAQ:WMIH) Exploring Financing Alternatives

WMIH Corp. (NASDAQ:WMIH)

WMIH Corp. (NASDAQ:WMIH) traded higher in Tuesday’s trading session a day after announcing it had retained Keefe, Bruyette & Woods to provide financial advisory services. The company’s shares experienced unusually high trading volume and rose by 8.7% to $1.25 a share.

Stock Performance

WMIH Corp. (NASDAQ:WMIH) faces immediate resistance at the $1.35 mark above which the stock could rally to $1.60. Shares of the company have been trading within a range of between $2.50 and $1.25 over the past year.

WMIH Corp. (NASDAQ:WMIH)
One month stock price chart for WMIH

WMIH Corp. (NASDAQ:WMIH) engages in the reinsurance business – specializing in mortgage insurance. Since emerging from bankruptcy on March 19, 2012, the company has been actively seeking acquisition opportunities across a broad array of industries with a specific focus on the financial services business.

The firm’s management team has been inactive on the dissemination of news that investors can use to gauge WMIH Corp. (NASDAQ:WMIH) long term prospects. However, the Chairman of the Board, Steve Scheiwe, in a recent press release reiterated a commitment to deliver value to shareholders.

“We remain committed to consummating an accretive acquisition transaction and to delivering value to our stockholders. However, we are mindful that the Company’s Series B Convertible Preferred Stock is redeemable on January 5, 2018, if we have not consummated, or executed a definitive agreement to consummate, a qualified acquisition prior to that date,” said Mr. Scheiwe.

WMIH Corp. (NASDAQ:WMIH) Finance Committee has tasked Keefe Bruyette & Woods with the responsibility of reviewing the company’ capital structure and potential financing alternatives.

Earnings Report

Separately, WMIH Corp. (NASDAQ:WMIH) generated revenues of $2,032 for the three months ended June 30, 2017, compared to revenues of $1,389 generated in Q2 2016. Net operating loss more than tripled to $4,058 from $546 reported last year. WMIH net loss attributable to common and participating stockholders in the quarter came in at $25,824 up from a net loss of $17,909 reported in Q2 2016. Net loss for the six months ended June 30, 2017, totaled $3,535 compared to a net income of $77,959 reported last year.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $WMIH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)

Market Ignores ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) Patent Award

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) rose on news that the biopharmaceutical firm was issued a patent, US 9,714,271, covering a broad collection of cyclophilin inhibitors. The newly granted patent significantly extends the claims of the original CRV431 patent family. News about the patent caused CTRV shares to open on their inter-day high, $0.65, before sellers stepped in a sent the stock back down $0.01 below Friday’s close of $0.60.

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)
One month stock price chart for CTRV

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) is a biopharmaceutical company that develops antiviral drugs with an emphasis on the treatment of Hepatitis B virus (HBV) infections. ContraVir currently has a lead cyclophilin inhibitor, CRV431 (US Patent 9,200,038), for use as an antiviral which ContraVir is developing as a treatment for the hepatitis B virus (HBV). The Company believes that CRV431 will be used in conjunction with tenofovir exalidex (TXLTM), its lead drug currently in Phase 2 clinical trials.

James Sapirstein, Chief Executive Officer of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) stated in the press release, “We are very pleased to have received the issuance of this additional patent, as it provides broad coverage of many compounds within our library of cyclophilin inhibitors. This also positions us for opportunities to potentially treat other diseases. Having a patented portfolio of cyclophilin inhibitors allows us to access additional disease indications and potentially expand beyond our core program in HBV.”

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) has posted losses every year since 2012 when it reported a loss of (-).02) per share followed by annual per share losses of (-$0.41), (-$1.02), and, for 2016 a loss of (-$0.63) per share. Meanwhile the company has diluted shareholders each year. In 2013, there were 9 million shares outstanding and by 2016 that number grew to 27.06 million. The analyst’s consensus target price for CTRV shares if $6.00.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CTRV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Stein Mart, Inc. (NASDAQ:SMRT)

More Bad News for Stein Mart, Inc. (NASDAQ:SMRT)

Stein Mart, Inc. (NASDAQ:SMRT)

Stein Mart, Inc. (NASDAQ:SMRT) shares are down over 5% in early trading but have rebounded from the day’s lows after the company released their Q2 financial results. Trading volume is moderately heavy. Importantly, there is a large short-selling position which accounts for over 25% of the stock’s float.

Stein Mart, Inc. (NASDAQ:SMRT)
One month stock price chart for SMRT

The drop in shares of Stein Mart, Inc. (NASDAQ:SMRT) was motivated by a reported decrease in total sales of 2.7% while comparable store sales decreased 5.0 %. Those sales resulted in a loss of (-$0.28) per diluted share of $0.28 compared to diluted earnings per share of $0.06 in 2016. Average store inventories were posted at 15 percent lower than at the same time last year.

Headquartered in Jacksonville, Florida, Stein Mart, Inc. (NASDAQ:SMRT) is a national clothing and household product retailer. Stein Mart offer an experience that is more upscale than other discount retailers, with a focus on ease-of-shopping, service and presentation of merchandise by category, brand, style and size. Stein Mart’s target customer is both style conscious and value seeking with above-average household income. Stein Mart operates nearly 300 stores in 31 states.

Stein Mart, Inc. (NASDAQ:SMRT) was trading north of $12 in 2015 but the shares have been in freefall since late 2016. YTD SMRT stock is down over 77% and down over 85% for the year. Shares are receiving support at the $1 level. Sales have marginally improved over the years but have been flat the last two years at $1.36 billion. Meanwhile there was a major drop in earnings per share. In 2015 EPS was $0.60, then for 2016 it was $0.52. Those figures were followed by an EPS of just $0.01 for 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SMRT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Netlist, Inc. (NASDAQ:NLST)

Netlist, Inc. (NASDAQ:NLST) Tanks

Netlist, Inc. (NASDAQ:NLST)

Netlist, Inc. (NASDAQ:NLST) stock is down almost 30%, to $0.60, at the opening of the market on a volume figure that indicates trading at over 127 times the daily average. Traders are reacting to the company’s pricing of its public offering of 8.5 million shares of its common stock at a price of $0.60 per share. Netlist has also granted the underwriters a 30-day option to purchase an additional 1.275 million shares of its common stock at $0.60 per share if the need arises to cover any over-allotments. The offering is expected to close on or about August 22, 2017.

Netlist, Inc. (NASDAQ:NLST)
One month stock price chart for NLST

The total gross proceeds are expected to be approximately $5.1 million. After deducting expenses, the net proceeds are expected to be approximately $4.5 million (assuming no exercise of the underwriters’ over-allotment option). The net proceeds will be used by Netlist, Inc. (NASDAQ:NLST) for general corporate purposes, including working capital and other general and administrative purposes.

The current slide in the price of NLST began on August 10, after Netlist, Inc. (NASDAQ:NLST) released Q2 2017 financials. The company’s net loss for the second quarter ended July 1, 2017, was (-$3.8) million, or (-$0.06) loss per share, compared to a net loss for the same period in the prior year of (-$1.5) million, or (-$0.03) loss per share. The slide has continued through the announcement of the dilutive public offering as NLST shares have hit new 52-week lows, eclipsing the old low of $0.83.

Irvine, CA-based Netlist, Inc. (NASDAQ:NLST) is a global provider of high-performance modular memory subsystems to original equipment manufacturers. Netlist specializes in hybrid memory – the merging of DRAM and NAND flash raw materials to create memory solutions. The Company’s patented memory technologies claims to supply superior performance, and high density in a cost-efficient solution.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NLST and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Singlepoint Inc (OTCMKTS:SING)

Singlepoint Inc (OTCMKTS:SING) Drops

Singlepoint Inc (OTCMKTS:SING)

Singlepoint Inc (OTCMKTS:SING) stock lost 17.5% today to close at $0.0693 on a volume figure in excess of 46 million. The loss was surprising given the announcement of a publication’s editorial featuring SinglePoint, Inc. (OTCMKTS:SING). The Network News Wire (NNW) publication focused on Singlepoint’s strengthening position in the legal cannabis industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication is titled, “Record Bitcoin Gains Indicate High Times Ahead for Cannabis Cryptocurrency,”. The editorial’s content discusses the potential of cryptocurrencies, such as Bitcoin or Ethereum, to serve as a solution for the cannabis sector’s inability to access the traditional banking system.

Singlepoint Inc (OTCMKTS:SING) has grown from a full-service mobile technology provider to a publicly traded holding company. Through diversification into horizontal markets, Singlepoint Inc (OTCMKTS:SING) is building its portfolio by acquiring interests in undervalued subsidiaries, thereby diversifying its potential revenue base. Through its subsidiary company, SingleSeed, the company is providing products and services to the cannabis industry.

While addressing Singlepoint’s cryptocurrency entry, the editorial stated “”SinglePoint’s bitcoin application will be KYC-AML compliant. Customers will be able to sign up for an account online prior to visiting a merchant, or they can do it in seconds right at the point of sale. Similar solutions have been deployed internationally, but SinglePoint is in an early-mover position to bring such technology to the United States. Though still a few months from its beta launch for the solution, SinglePoint is already amassing potential customers through its website.”

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SING and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.